PharmaCielo (OTCMKTS:PCLOF) is a Colombia-based, vertically integrated cannabinoid extraction and manufacturing company that develops pharmaceutical-grade active ingredients for the global medical cannabis market. The company specializes in the cultivation, extraction, purification and isolation of cannabinoids, producing a range of high-purity oils, distillates and isolates that serve as the active pharmaceutical ingredients (APIs) in end-use formulations. PharmaCielo’s product portfolio is designed to meet Good Manufacturing Practices (GMP) standards, enabling partnerships with pharmaceutical firms and wellness brands seeking compliant, consistently standardized cannabinoid inputs.
Since commencing operations, PharmaCielo has established a state-of-the-art extraction facility in Colombia, leveraging the country’s favorable agronomic conditions and regulatory framework for medicinal cannabis cultivation. The company’s fully integrated model—from seed to final product—allows for rigorous quality control at each stage, including proprietary winterization and distillation processes that yield >99% purity cannabinoids. In addition to its in-house product offerings, PharmaCielo provides tolling and white-label services for third-party cultivators and brand owners seeking scalable extraction solutions.
PharmaCielo’s operations are supported by partnerships with local growers and regulatory authorities, including Colombia’s Ministry of Health and the National Institute for Food and Drug Surveillance. The company primarily serves markets in North America and Europe, where patient demand for medical cannabis and related derivatives continues to expand. PharmaCielo’s ability to navigate the changing regulatory landscape and maintain EU GMP compliance has been central to its strategy of supplying Global Good Agricultural and Collection Practices (GACP)–certified cannabinoid inputs to pharmaceutical and nutraceutical customers.
Founded in the mid-2010s and publicly listed in Canada, PharmaCielo has grown its production capacity through phased expansion plans and capital partnerships. The management team combines expertise in pharmaceutical development, agricultural science and international operations to position the company as a reliable supplier of clinical-grade cannabinoids. As global regulators and healthcare providers increasingly recognize the therapeutic potential of cannabis-derived APIs, PharmaCielo aims to leverage its specialized extraction technology and Latin American production base to capture a leading share of the emerging market for standardized cannabinoid products.
AI Generated. May Contain Errors.
